Sally Adams
Direktor/Vorstandsmitglied bei Scancell Ltd.
Vermögen: 10 122 $ am 31.05.2024
Profil
Sally Elizabeth Adams is currently a Director & Development Director at Scancell Ltd.
She previously worked as an Executive Director & Chief Development Officer at Scancell Holdings Plc, a Development Director at Neures Ltd., and Head-Neurology & Virology at Ligand UK Ltd.
Adams holds a doctorate from Imperial College London and a graduate degree from the University of Cambridge.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SCANCELL HOLDINGS PLC
0,01% | 19.12.2023 | 78 714 ( 0,01% ) | 10 122 $ | 31.05.2024 |
Aktive Positionen von Sally Adams
Unternehmen | Position | Beginn |
---|---|---|
Scancell Ltd.
Scancell Ltd. Miscellaneous Commercial ServicesCommercial Services Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Sally Adams
Unternehmen | Position | Ende |
---|---|---|
SCANCELL HOLDINGS PLC | Direktor/Vorstandsmitglied | 05.02.2024 |
VERNALIS | Corporate Officer/Principal | - |
Neures Ltd. | Corporate Officer/Principal | - |
Ausbildung von Sally Adams
University of Cambridge | Graduate Degree |
Imperial College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SCANCELL HOLDINGS PLC | Health Technology |
Private Unternehmen | 3 |
---|---|
Neures Ltd. | |
Ligand UK Ltd.
Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Scancell Ltd.
Scancell Ltd. Miscellaneous Commercial ServicesCommercial Services Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom. | Commercial Services |